Mirum Pharmaceuticals (MIRM) Retained Earnings (2018 - 2026)

Mirum Pharmaceuticals' Retained Earnings history runs 9 years deep, the most recent figure standing at -$1.5 billion for Q1 2026.

• On a quarterly basis, Retained Earnings fell 581295.35% year-over-year to -$1.5 billion in Q1 2026; TTM through Mar 2026 was -$1.5 billion, a 581295.35% decrease from a year earlier, with the FY2025 full-year figure at -$667.5 million, down 3.63% from the prior year.
• Retained Earnings fell to -$1.5 billion in Q1 2026 per MIRM's latest filing, from -$667.5 million in the prior quarter.
• Across five years, Retained Earnings topped out at $920000.0 in Q3 2024 and bottomed at -$1.5 billion in Q1 2026.
• The 5-year median for Retained Earnings is -$423.0 million (2023), against an average of -$403.2 million.
• Across the five-year window, Retained Earnings tumbled 1122254.29% in 2022 and soared 163.1% in 2024, its largest moves.
• Year by year, Retained Earnings stood at -$392.8 million in 2022, then slumped by 41.6% to -$556.2 million in 2023, then dropped by 15.81% to -$644.2 million in 2024, then slipped by 3.63% to -$667.5 million in 2025, then tumbled by 124.7% to -$1.5 billion in 2026.
• Per Business Quant, the three latest MIRM Retained Earnings figures stand at -$1.5 billion (Q1 2026), -$667.5 million (Q4 2025), and $37000.0 (Q3 2025).